As we approach the last of our exclusive coverage of ASCO 2023, editor-in-chief Jonah Comstock speaks with Mark Reisenauer, president of US commercial at Astellas.
While ASCO 2023 didn’t have too much focus on cell therapies, because of their lack of impact so far on the solid tumour space, Kite, a Gilead company, did share new data on Yescarta for la
In another look back to ASCO 2023, pharmaphorum editor-in-chief Jonah Comstock spoke with Janssen's Martin Vogel and Edmond Chan, EMEA leads for oncology and haematology, respectively.
At ASCO 2023 last week in Chicago, editor-in-chief Jonah Comstock caught up with Dr Corina Dutcus, SVP clinical development at Eisai US, to talk about the CLEAR trial, one of Eisai’s major